Prime Medicine, Inc. Shareholders' Equity
Prime Medicine, Inc. (PRME) had Shareholders' Equity of $39.81 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $39.81M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $76.70M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $120.87M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $161.82M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $39.81M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $76.70M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $120.87M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $161.82M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $60.86M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $106.92M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $153.15M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $189.50M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $196.59M 10-Q · filed 2025-11-07 | |
| 2024-03-31 | $243.77M 10-Q · filed 2025-11-07 | |
| 2023-12-31 | $133.07M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $193.96M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $240.10M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $278.80M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $316.27M 10-K · filed 2025-02-28 | |
| 2022-09-30 | -$223.10M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | -$195.06M 10-Q · filed 2023-11-03 | |
| 2022-03-31 | -$166.94M 10-Q · filed 2023-11-03 | -$166.94M 10-Q · filed 2022-11-14 |
| 2021-12-31 | -$156.24M 10-K · filed 2024-03-01 | |
| 2021-09-30 | -$94.42M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$78.37M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | -$85.31M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $2.34M 10-K · filed 2023-03-09 | |
| 2019-12-31 | -$2.60M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |